The DOI matches its Crossref record.
Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients
Abstract
BACKGROUND: Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection. Everolimus blocks growth factor-mediated transduction signals, preventing organ rejection by a mechanism different than that of calcineurin inhibitors and of mycophenolate mofetil (MMF). METHODS.: Everolimus (1.5 mg or 3 mg daily) was compared with MMF (2 g daily) in a randomized, multicenter, multinational, 12-month double-blind, double-dummy and 2-year open-label, phase 3 trial in de novo renal allograft recipients (n = 588) who also received cyclosporine and corticosteroids as part of a triple immunosuppressive regimen. RESULTS: At 12 months, there were no statistically significant differences between doses of 1.5 and 3 mg/day everolimus and MMF (2 g/day) in incidence of biopsy-proven acute rejection (23.2%, 19.7%, and 24.0%, respectively), graft loss (4.6%, 10.6%, and 9.2%), or death (5.2%, 4.0%, and 2.6%), respectively. Everolimus 1.5 mg/day and MMF were generally equally well tolerated. Both were better tolerated than everolimus 3 mg/day. The incidence of cytomegalovirus infection was significantly lower in patients receiving either 1.5 or 3 mg/day everolimus than in those receiving MMF (5.2% and 7.6% vs. 19.4%, respectively) (P = .001). CONCLUSIONS: Everolimus is effective in preventing acute rejection and graft loss in de novo renal allograft recipients receiving a triple immunosuppressive regimen. Prevention of acute rejection, along with reduction in cytomegalovirus infection, addresses two factors known to contribute to chronic rejection in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chronic Renal Allograft Dysfunction
Chapman, J. R., O’Connell, P. J., & Nankivell, B. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050463 · Cited by 436
Webster, A. C., Lee, V. W. S., Chapman, J. R., & Craig, J. C. (2006) · Transplantation · doi:10.1097/01.tp.0000219703.39149.85 · Cited by 335
Silva Jr., H. T., Cibrik, D., Johnston, T., Lackova, E., Mange, K., Panis, C., Walker, R., Wang, Z., Zibari, G., & Kim, Y. S. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03129.x · Cited by 269
Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients
Kasiske, B. L., de Mattos, A., Flechner, S. M., Gallon, L., Meier-Kriesche, H.-U., Weir, M. R., & Wilkinson, A. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02272.x · Cited by 163
Nelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Metadata
- Authors
- Vítko, Š., Margreiter, R., Weimar, W., Dantal, J., Viljoen, H. G., Li, Y., Jappe, A., & Cretin, N.
- Venue
- Transplantation
- Published
- 2004-11-27
- Volume
- 78
- Issue
- 10
- Pages
- 1532-1540
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2094665185
- Cited by
- 160
- References
- 0
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients. https://app.cochat.ai/papers/10.1097/01.tp.0000141094.34903.54
- The paper
- Vítko, Š., Margreiter, R., Weimar, W., Dantal, J., Viljoen, H. G., Li, Y., Jappe, A., & Cretin, N. (2004). Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients. Transplantation. https://doi.org/10.1097/01.tp.0000141094.34903.54
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.